Not sure where to start? Get matched →
All of Tirzepatide (Injectable)
Alabama

Tirzepatide (Injectable) in Alabama

Doctor-prescribed Tirzepatide (Injectable) for Alabama residents. Reviewed by licensed Alabama physicians, compounded at FDA-registered pharmacies, and shipped to your door.

All-in monthly price

$159

No membership fee · this is the full price · free shipping · avg 4-week supply

Medication, provider care, labs & dose adjustments — all in one price.
~28-day supply. Your provider sets your exact dose, so yours may vary — your refill arrives as you finish the last one.
Start assessment

Add in-depth bloodwork

Optional — add a physician-reviewed at-home blood panel to your plan.

At-home kit (1 device)+$149

Your sex-hormone baseline plus the safety markers that matter on therapy — blood counts, liver and kidney function — from one painless upper-arm device. Matched to your sex (PSA for men; progesterone & FSH for women). No needle, no clinic, physician-reviewed.

Money-back guarantee
Free AI care assistant
HSA/FSA accepted
Cancel anytime
Free shipping

This treatment requires licensed provider review and approval. Treatment is not guaranteed. If prescribed, medication is fulfilled by a licensed U.S. pharmacy where permitted by law. Compounded medications are not FDA-approved or FDA-cleared.

Dr. Gene
Physician Reviewed

Reviewed by Dr. Gene, MD · Board-certified Family Medicine

Every Pepti prescription is reviewed by a licensed U.S. physician before it's dispensed — and only provided if clinically appropriate.

The process

How it works in Alabama

  1. 1Complete a free online intake (~5 minutes).
  2. 2A licensed Alabama physician reviews your case within 24 hours.
  3. 3Your prescription ships from our FDA-registered compounding pharmacy.
  4. 4Free shipping arrives 2–4 business days later. Refills ship automatically when your supply runs out — cancel anytime.
The treatment

What Tirzepatide (Injectable) does

Dual GIP and GLP-1 receptor agonist offering enhanced weight management benefits.

✓Dual GIP/GLP-1 action
✓Superior weight loss
✓Metabolic health
✓Appetite reduction
Formulation
Injectable vial2 mL
Tirzepatidecompounded to your dose
Cyanocobalamin (B12)included

Strength is compounded to the exact dose your physician prescribes and stepped up over time; paired with B6 to ease nausea.

Amounts shown are per unit. Compounded fresh at a US FDA-registered pharmacy.

Quality

Every batch independently tested

Every medication batch dispensed through Pepti is independently tested by a qualified third-party laboratory for applicable quality and safety standards before the pharmacy releases it. Batches are tested to the same standard used by 503B outsourcing facilities.

Sterility

USP <71>

Confirms the finished preparation is free of viable microorganisms.

Bacterial endotoxins

USP <85>

Screens for endotoxins that can cause fever or inflammatory reactions.

Potency

Assay

Verifies the labeled concentration of the active peptide is what is in the vial.

Purity

HPLC

Checks the active peptide against impurities and degradation products.

Identity

Mass spectrometry

Confirms the peptide in the vial is the correct molecule.

pH

USP <791>

Confirms the solution sits within the range specified for injection.

Particulate matter

USP <788>

Checks the finished vial for visible and sub-visible particles.

Container closure integrity

USP <1207>

Confirms the vial seal holds so sterility is maintained through the beyond-use date.

Recent lots

  • Lot 100526-TIR-10

    Tested 2026-10-07 · Biolink Life Sciences Carolinas

    Sterility

    Sterile

    Endotoxin

    <2 EU/mL

    Potency

    99.2%

  • Lot 100526-TIR-20

    Tested 2026-10-07 · Biolink Life Sciences Carolinas

    Sterility

    Sterile

    Endotoxin

    <2 EU/mL

    Potency

    100.2%

  • Lot 100526-TIR-30

    Tested 2026-10-07 · Biolink Life Sciences Carolinas

    Sterility

    Sterile

    Endotoxin

    <2 EU/mL

    Potency

    99.4%

Compounded by licensed U.S. pharmacies. Prescribed by licensed medical providers. Shipped directly to patients in Alabama.Documentation available upon request →View lab results by lot →
Alabama

Telemedicine in Alabama.

Alabama permits telehealth prescribing under Alabama Board of Medical Examiners rules. An Alabama-licensed physician can establish the patient relationship through online intake review — no in-person visit is required for peptide or GLP-1 prescribing. Pepti is available in all 50 states and Washington, D.C.

Alabama is among the states with the highest adult obesity prevalence, driving strong demand for GLP-1 and metabolic peptide therapy via telehealth.

Alabama cities Pepti serves

Pepti delivers Tirzepatide (Injectable) to patients across Alabama, including Birmingham, Montgomery, Huntsville, Mobile, Tuscaloosa, Hoover, Auburn, Dothan, Madison, Decatur, Florence, Prattville
+ 13 more cities, Phenix City, Vestavia Hills, Alabaster, Opelika, Gadsden, Northport, Athens, Daphne, Enterprise, Homewood, Trussville, Pelham, Bessemer
. All shipments use the same FDA-registered compounding pharmacy regardless of city.

Weight management in Alabama

The CDC reports 35%+ (CDC 2023) adult obesity prevalence in Alabama, well above the threshold where GLP-1 therapy demonstrates significant clinical benefit. Tirzepatide (Injectable) is prescribed in Alabama when BMI thresholds and intake criteria are met under physician review.

Your protocol

How Tirzepatide is prescribed in Alabama.

Who it's for

  • Adults with a BMI in the range their physician considers appropriate for dual GIP/GLP-1 therapy
  • Patients who did not reach their goal on semaglutide
  • People who want physician-managed dose escalation rather than a fixed dose
  • Patients already on tirzepatide who want to continue at their current dose

Your physician decides whether Tirzepatide is appropriate for you after reviewing your intake and labs.

Directions & duration

Inject 0.50 mL (50 units) subcutaneously once weekly.

Cycle. Weekly injection. New to it? Dose steps up on a schedule set by your physician; you can request the next step when you're ready. Already on it? Choose your current dose when you order and your physician confirms it at review. Pricing is by dose.
Ready for more? When you're ready, ask your physician to step up to the next dose. Approved steps are charged at the price difference and applied to your next fill.
Directions shown are the pharmacy's standard for this preparation. Your prescription label is the final word.

What's included

  • Licensed physician review of your intake, history, and labs
  • Medication compounded to your prescription by a PCAB-accredited, FDA-registered pharmacy
  • Every batch independently tested before release
  • Sterile syringes and alcohol prep pads for injectables
  • Tracked delivery to your door, refills on schedule
  • Message your physician anytime; dose changes without an appointment

Storage & handling

  • Store refrigerated (36–46°F / 2–8°C) at all times, including before first use.
  • One vial is your monthly supply. A fresh vial ships to your Alabama address every 28 days on your refill schedule, so you're always well inside the beyond-use date on your label.
  • Protect from light. Wipe the stopper with an alcohol pad before every draw.
  • Dispose of syringes in the sharps container per the included instructions.

What to expect

A typical course of Tirzepatide in Alabama.

TimeframeWhat patients commonly report
Weeks 1–4Reduced appetite and earlier fullness are the most common first changes. Mild nausea is common while the body adjusts; for patients new to the medication the starting dose is deliberately low. Already on it? Your provider can continue you at the dose you're on.
Weeks 5–12As the dose steps up under physician direction, weight change typically becomes measurable. Slower is safer.
Month 3 onwardOngoing physician monitoring; long-term results in studies depended on continued treatment alongside diet and activity.
Individual results vary. Compounded medications are not FDA-approved; a licensed physician determines whether treatment is appropriate and monitors your progress.

The science

How Tirzepatide works, and what the research shows.

How it works

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both incretin pathways instead of just one.

This dual action produces superior weight loss results vs semaglutide alone.

Phase 3 trials showed up to 22.5% body weight loss.

Clinical evidence

  • The SURMOUNT-1 trial randomized 2,539 adults with obesity to tirzepatide 5/10/15 mg vs placebo.

    Jastreboff et al., NEJM 2022
  • At 72 weeks, mean weight reductions were 15.0%, 19.5%, and 20.9% on the active arms vs 3.1% on placebo — the highest weight-loss outcomes recorded for a pharmacological intervention at the time.

  • SURMOUNT-2 confirmed efficacy in patients with type 2 diabetes, and the SURPASS program demonstrated superior HbA1c reduction vs semaglutide head-to-head.

    Frias et al., 2021
  • Tirzepatide's dual GIP+GLP-1 mechanism appears to drive both stronger appetite suppression and improved metabolic flexibility.

Full references with PubMed links are listed further down the page.

References

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) · New England Journal of Medicine (2022) · PMID 35658024
  2. Garvey WT, Frias JP, Jastreboff AM, et al.. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) · Lancet (2023) · PMID 37385275
  3. Frías JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) · New England Journal of Medicine (2021) · PMID 34170647
  4. Inagaki N, Takeuchi M, Oura T, et al.. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial · The Lancet Diabetes & Endocrinology (2022) · PMID 35468322
  5. Malhotra A, Grunstein RR, Fietze I, et al.. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) · New England Journal of Medicine (2024) · PMID 38912654
  6. Nicholls SJ, Pavo I, Bhatt DL, et al.. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT) · New England Journal of Medicine (2025) · PMID 41406444
  7. Aronne LJ, Sattar N, Horn DB, et al.. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial · JAMA (2024) · PMID 38078870
  8. Pasternak B, Wintzell V, Hviid A et al.. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study · BMJ (2024) · PMID 38683947
  9. Quddos F, Hubshman Z, Tegge A, et al.. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity · Scientific Reports (2023) · PMID 38017205
  10. Drummond RF, Seif KE, Reece EA. Glucagon-like peptide-1 receptor agonist use in pregnancy: a review · Am J Obstet Gynecol (2025) · PMID 39181497
  11. Wang S, Sun J, Wang J, et al.. Does obesity based on body mass index affect semen quality? A meta-analysis and systematic review from the general population rather than the infertile population · Andrologia (2021) · PMID 34028074
  12. Urva S, Coskun T, Loghin C, et al.. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists · Diabetes, Obesity and Metabolism (2020) · PMID 32519795
  13. Borner T, Geisler CE, Fortin SM, et al.. GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models · Diabetes (2021) · PMID 34380697
  14. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment · N Engl J Med (2001) · PMID 11372012
  15. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it · Int J Epidemiol (2005) · PMID 15333621
  16. McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects · J Clin Epidemiol (2014) · PMID 24275499
  17. Heise T, DeVries JH, Urva S, et al.. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes · Diabetes Care (2023) · PMID 36857477
  18. Schneck K, Urva S. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide · CPT Pharmacometrics Syst Pharmacol (2024) · PMID 38356317
  19. Bochanen N, Decochez K, Heleu E, Cuypers J, et al.. Lipohypertrophy Monitoring Study (LIMO): Effect of single use of 4 mm pen needles combined with education on injection site rotation on glycaemic control: Confirmation of an unpleasant truth · Diabet Med (2022) · PMID 34407260
  20. Murao S, Murao K, Nagata T, Shimizu M. Repeated insulin injection without site rotation affects skin thickness - ultrasonographic and histological evaluation · J Diabetes Investig (2022) · PMID 35060349
  21. Deng N, Zhang X, Zhao F, Wang Y. Prevalence of lipohypertrophy in insulin-treated diabetes patients: A systematic review and meta-analysis · J Diabetes Investig (2017) · PMID 28862814
  22. Wadden TA, Chao AM, Machineni S, et al.. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial · Nature Medicine (2023) · PMID 37840095
  23. Rosenstock J, Wysham C, Frías JP, et al.. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial · Lancet (2021) · PMID 34186022
  24. Ludvik B, Giorgino F, Jódar E, et al.. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial · Lancet (2021) · PMID 34370970
  25. Del Prato S, Kahn SE, Pavo I, et al.. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial · Lancet (2021) · PMID 34672967
  26. Dahl D, Onishi Y, Norwood P, et al.. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial · JAMA (2022) · PMID 35133415
  27. Guo L, Klonoff DC, Al Sifri SN, Bee YM et al.. Consensus Recommendations on Lipohypertrophy: Insights From an International Panel of Experts · Diabetes Research and Clinical Practice (2026) · PMID 42398590
  28. Sattar N, Linetzky B, Ruotolo G et al.. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis · J Am Coll Cardiol (2026) · PMID 42233927
  29. Coskun T, Sloop KW, Loghin C, et al.. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept · Molecular Metabolism (2018) · PMID 30473097
  30. Sattar N, McGuire DK, Pavo I, et al.. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis · Nature Medicine (2022) · PMID 35210595
  31. Samms RJ, Coghlan MP, Sloop KW. A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity · Diabetes (2025) · PMID 40521890
  32. Wang L, Wang N, Zhang W et al.. Therapeutic peptides: current applications and future directions · Signal Transduct Target Ther (2022) · PMID 35165272

Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.

Pharmacy network accreditation

PCAB-accredited pharmacies on every order.

Every fulfillment runs through a PCAB-accredited pharmacy.

See the lab results
PCAB — Pharmacy Compounding Accreditation Board · Accredited
  • Rigorous third-party quality & safety inspections
  • Cleanliness and sterile processes
  • Proper ingredient sourcing
  • Accurate dosing and formulation
  • Staff training and procedures
  • Accredited by NABP & ACHC
Common questions

Frequently asked
about Tirzepatide (Injectable) in Alabama.

Yes. Tirzepatide (Injectable) is legal when prescribed by a physician licensed in Alabama and dispensed by an FDA-registered compounding pharmacy. Alabama permits telehealth prescribing under Alabama Board of Medical Examiners rules. An Alabama-licensed physician can establish the patient relationship through online intake review — no in-person visit is required for peptide or GLP-1 prescribing.

33 more questions about Pepti, answered.

Pepti serves all of Alabama. A physician licensed in Alabama reviews every order within 4 hours, the prescription is compounded by a state-licensed, FDA-registered pharmacy, and it ships free and tracked to any Alabama street address. The price is the same as every other state.

Pepti operates in Alabama through licensed physician partnerships. Compounded medications are produced at FDA-registered 503A pharmacies. Treatment decisions are made by your prescribing physician.